Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis,
in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical
studies of targeted radiotracers. The importance of the target to a key ... click here for full Aims & Scope
Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis,
in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical
studies of targeted radiotracers. The importance of the target to a key disease should be the first consideration. If the synthesis of
a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.
These multidisciplinary studies should demonstrate the mechanism of localization whether the probe is based on binding to a receptor,
enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical properties and radiopharmaceutical
preparation affect pharmacokinetics, pharmacodynamics, and therapeutic efficacy. Ideally, the study would address the sensitivity of
the probe to changes in biochemistry, although studies of mechanism alone are acceptable. Radiopharmacy practice, addressing the issues
of preparation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to
humans, are also encouraged.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that
the specificity of labeled compound localization and therapeutic effect have been addressed. Studies that describe instrumentation important
to molecular are also encouraged.
Hide Aims & Scope
Editor-in-Chief: Contact the Editor
William C. Eckelman, PhD
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company